Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 131-144

  Faller, Bryan A ^a   Pandit, Trailokya N ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Cetuximab; Chemotherapy; Geriatrics; Non small cell lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ACNE; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; EXTRAVASATION; FATIGUE; FEBRILE NEUTROPENIA; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIVER FUNCTION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; RASH; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

EID: 79958054933     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S5074     Document Type: Review

References (47)

1. Altekruse SF, Kosary CL, Krapcho M, et al, editors. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Lung and Bronchus. National Cancer Institute's SEER Website. Available at: http://seer.cancer. gov/statfacts/html/lungb.html. Accessed January 27, 2011.
2. Altekruse SF, Kosary CL, Krapcho M, et al, editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. November 2009 SEER Data Submission Website. Available at: http://seer.cancer.gov/ csr/1975_2007/. Accessed January 27, 2011.
3. Travis WD, Travis LB, Devesa SS. Lung cancer. Jan 1. Cancer. 1995; 75(1 Suppl):191-202.
4. Sugimura H, Nicolas FC, Yang P, et al. Survival after recurrent non smallcell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409-418.
5. AlbainKS, Crowley JJ, Le Blanc M, et al. Survival determinants in extensive- stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618-1626.
6. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899-909.
7. Potier P. Navelbine. "History of the discovery of Navelbine". In: Solal- Celigny P, editor. Navelbine (vinorelbine): update and new trends. John Libbey Eurotext Ltd; 1991:3-8.
8. Toso C, Lindley C. Vinorelbine a novel vinca alkaloid. Am J Health Syst Pharm. 1995;52(12):1287-1304.
9. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of Navelbine in humans as determined by high performance liquid chromatography. Cancer Res. 1991;51:2073-2076.
10. Feigal EG, Christian M, Cheson B, et al. New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol. 1993;20:185-201.
11. Marty M, Fumoleau P, Adenis A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann of Oncol. 2001;12:1643-1649.
12. Krikorian A, Rahmani R, Bromet M, et al. Pharmacokinetics and metabolism of Navelbine. Semin Oncol. 1989;16(Suppl 4):21-25.
13. Mouchard-Delmas C, Gourdier B, Vistelle R, et al. Modification of the blood- brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion. Anticancer Drugs. 1996; 7(2):213-219.
14. Product Monograph: Vinorelbine Injection. Pharmaceutical Partners of Canada Inc., Vinorelbine CCO Formulary Revised November 2010. Available at http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=10727. Accessed March 9, 2011.
15. Khayat D, Covelli A, Variol P, et al. Phase I and pharmacologic study of intravenous (IV) vinorelbine in patients with solid tumours. Proc Annu Soc Clin Oncol. 1995;14:469.
16. Mathe G, Reizenstein P. Phase I pharmacological study of a new vincaalkaloid: Navelbine. Cancer Lett. 1985;27:285-293.
17. Gregory RK, Smith IE. Vinorelbine-a clinical review. British J of Cancer. 2000;82(12):1907-1913.
18. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate. Oncol Nurs Forum. 1995;22:707-710.
19. Arriagada R, Bergman B, Dunat A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
20. Le Chevalier T, Dunant A, Arriagada R, et al. Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin- based chemotherapy in resected non-small cell lung cancer (NSCLC). J Clin Oncol. 2010, 1;28(1):35-42.
21. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59(10):828-836.
22. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10. J Clin Oncol. 2007;25:1553-1561.
23. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol. 2008;26:3552-3559.
24. Douillard JY, Helene T, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer. J Thorac Oncol. 2010;5: 220-228.
25. Faller B, Robu V, Borghaei H. Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer. Clin Lung Cancer. 2009;10(6):438-440.
26. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci. 2004;95:691-695.
27. Hirose T, Mizutani Y, Ohmori T, et al. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Ann Oncol. 2005;58(3):361-367.
28. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360-367.
29. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-328.
30. Ohe Y, Ohashi Y, Kuboto K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan. Ann Oncol. 2007;18:317-323.
31. Gebbia V, Galetta D, Lorusso V. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer. 2008;61:369-377.
32. Fossella F, Pereira JR, von Pawel J, et al. Randomized, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-3024.
33. Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every 3 weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(3):468-473.
34. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009;27:15s(Suppl; Abstr 8001).
35. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens in advanced non-small cell lung cancer. N Engl J Med. 2002; 346(2): 92-98.
36. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:499-506.
37. The Elderly Lung Cancer Vinorelbine Italian Study. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999;91(1):66-72.
38. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26(26):4253-4260.
39. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Nat Cancer Inst. 2003;95:362-372.
40. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2000;18:2529-2536.
41. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT -0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2010;28:18s(Suppl; Abstr2).
42. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med. 2009;361:947-957.
43. Pujol JL, Viens P, Rebattu P, et al. Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. J Thorac Oncol. 2006;1:417-424.
44. Priker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525-1531.
45. Ettinger D, Akerley W, Borghaei H, et al. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer. NCCN Website. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed January 27, 2011.
46. Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatments, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3:1286-1292.
47. Joerger M, Matter-Walstra K, Fruh M, et al. Addition of cetuximab to firstline chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol. 2011;22:567-574.